Drug Profile
Proxison
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Antoxis
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Neurodegenerative disorders; Parkinson's disease; Stroke
Highest Development Phases
- Discontinued Parkinson's disease; Stroke
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Parkinson's disease in United Kingdom (unspecified route) (Antoxis pipeline, September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Stroke in United Kingdom (unspecified route) (Antoxis pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Parkinson's-disease in United Kingdom